Neoprobe tests radiotracer in melanoma trial:
This article was originally published in Clinica
Neoprobe is to begin a US clinical trial of its investigational lymphatic radiotracer in melanoma patients. The study, supported by a $250,000 grant from the American Cancer Society, will evaluate use of the agent Tc-mannosyl-dextran as a means of identifying the sentinel lymph node in patients with the disease. The accurate determination of the spread of disease into the lymphatic system is important in establishing the appropriate type of treatment, says the Dublin, Ohio firm. A study assessing use of the agent in the treatment of breast cancer is already underway in the US.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.